HMGCR and renal cell carcinoma: Many studies have shown that statins increase survival rates for cancer patients, including prostate cancer (PCa), lung cancer, gastric cancer (GC), renal cell carcinoma (RCC), breast cancer, colorectal cancer, ovarian cancer, pancreatic cancer, esophageal cancer, endometrial cancer, suggesting that HMGCR is a broad-spectrum anticancer and cardiovascular disease target 39, 40.